{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:52:23Z","timestamp":1767649943329,"version":"3.44.0"},"reference-count":51,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,2,11]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy through 52 weeks of guselkumab, an interleukin 23-p19 subunit inhibitor, in subgroups of pooled psoriatic arthritis (PsA) patients from the DISCOVER-1 and DISCOVER-2 trials defined by baseline patient characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with active PsA despite standard therapies were enrolled in DISCOVER-1 (\u22653 swollen and \u22653 tender joints, C reactive protein (CRP) level \u22650.3\u2009mg\/dL) and DISCOVER-2 (\u22655 swollen and \u22655 tender joints, CRP \u22650.6\u2009mg\/dL, biological-na\u00efve). Randomised patients received 100\u2009mg guselkumab at weeks 0, 4, and then every 4 or 8 weeks (Q4W\/Q8W) or placebo. Guselkumab effects on joint (ACR20\/50\/70), skin (IGA 0\/1, IGA 0), patient-reported outcome (Health Assessment Questionnaire Disability Index\/Functional Assessment of Chronic Illness Therapy-Fatigue) and disease severity (minimal disease activity\/PsA Disease Activity Score low disease activity) endpoints were evaluated by patient sex, body mass index, PsA duration, swollen\/tender joint counts, CRP level, percent body surface area with psoriasis, Psoriasis Area and Severity Index score, and conventional synthetic disease-modifying antirheumatic drug use at baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline patients characteristics in DISCOVER-1 (N=381) and DISCOVER-2 (N=739) were well balanced across randomised groups. At week 24, 62% (232\/373) and 60% (225\/375), respectively, of guselkumab Q4W-treated and Q8W-treated patients pooled across DISCOVER-1 and DISCOVER-2 achieved the primary endpoint of ACR20 response versus 29% (109\/372) of placebo-treated patients. Guselkumab treatment effect at week 24 was observed across patient subgroups. Within each patient subgroup, response rates across all disease domains were sustained or increased at week 52 with both guselkumab regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Guselkumab Q4W and Q8W resulted in robust and sustained improvements in PsA signs and symptoms consistently in subgroups of patients defined by diverse baseline characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03162796\">NCT03162796<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03158285\">NCT03158285<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002195","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:10:59Z","timestamp":1647432659000},"page":"e002195","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03162796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03158285","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T","family":"Ritchlin","sequence":"first","affiliation":[{"name":"Department of Medicine - Allergy\/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research, Swedish Medical Center\/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Tesser","sequence":"additional","affiliation":[{"name":"Arizona Arthritis & Rheumatology Associates, Phoenix, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-5292","authenticated-orcid":false,"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Internal Medicine, Michigan Medicine Rheumatology Clinic, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA"},{"name":"Rheumatology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa P","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Research and Development LLC, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xie L","family":"Xu","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Research and Development LLC, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Horsham, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Biostatistics, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihong","family":"Sheng","sequence":"additional","affiliation":[{"name":"Biostatistics, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[{"name":"Biostatistics, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Xu","sequence":"additional","affiliation":[{"name":"Biostatistics, Janssen Research and Development LLC, Spring House, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Dermatology and Medicine, Division of Rheumatology and Immunology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.1","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090313382518000_8.1.e002195.2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.3","DOI":"10.1136\/annrheumdis-2021-eular.4091"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.4","DOI":"10.1016\/j.jaad.2012.06.035"},{"key":"2025090313382518000_8.1.e002195.5","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","article-title":"Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study","volume":"40","author":"Lorenzin","year":"2021","journal-title":"Clin Rheumatol"},{"unstructured":"Janssen Biotech Inc . Tremfya: package insert. Horsham, PA, 2020. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf","key":"2025090313382518000_8.1.e002195.6"},{"key":"2025090313382518000_8.1.e002195.7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2020.1857733","article-title":"Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults","volume":"17","author":"Boehncke","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.8","DOI":"10.1016\/S0140-6736(20)30265-8"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.9","DOI":"10.1136\/rmdopen-2020-001457"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.10","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2025090313382518000_8.1.e002195.11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313382518000_8.1.e002195.12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-Term efficacy and safety of guselkumab, a monoclonal antibody specific to the P19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-na\u00efve patients with active psoriatic arthritis","volume":"74","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313382518000_8.1.e002195.13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025090313382518000_8.1.e002195.14","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.15","DOI":"10.1093\/rheumatology\/kew326"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.16","DOI":"10.1136\/rmdopen-2020-001486"},{"key":"2025090313382518000_8.1.e002195.17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313382518000_8.1.e002195.18","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s10067-020-05027-1","article-title":"Retention rates and identification of factors associated with anti-TNF\u03b1, anti-IL17, and anti-IL12\/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting","volume":"39","author":"Navarini","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090313382518000_8.1.e002195.19","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.20","DOI":"10.1136\/annrheumdis-2018-213474"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.21","DOI":"10.1007\/s10067-017-3593-x"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.22","DOI":"10.1016\/j.semarthrit.2017.02.001"},{"key":"2025090313382518000_8.1.e002195.23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjd.16008","article-title":"Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"178","author":"Gordon","year":"2018","journal-title":"Br J Dermatol"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.24","DOI":"10.1002\/art.1780380602"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.25","DOI":"10.1002\/1529-0131(199809)41:9%3C1564::AID-ART6%3E3.0.CO;2-M"},{"key":"2025090313382518000_8.1.e002195.26","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64 Suppl 2","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.27","DOI":"10.3109\/09546634.2013.865009"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.28","DOI":"10.1136\/ard.2006.065763"},{"key":"2025090313382518000_8.1.e002195.29","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.30","DOI":"10.1136\/annrheumdis-2012-201341"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.31","DOI":"10.1136\/ard.2008.102053"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.32","DOI":"10.1080\/14397595.2016.1193105"},{"key":"2025090313382518000_8.1.e002195.33","doi-asserted-by":"crossref","first-page":"482691","DOI":"10.1155\/2013\/482691","article-title":"Clinical differences between men and women with psoriatic arthritis: relevance of the analysis of genes and polymorphisms in the major histocompatibility complex region and of the age at onset of psoriasis","volume":"2013","author":"Queiro","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2025090313382518000_8.1.e002195.34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","article-title":"Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment","volume":"29","author":"Mease","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2025090313382518000_8.1.e002195.35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/2475530319870776","article-title":"Gender differences in psoriatic arthritis with fatigue, pain, function, and work disability","volume":"4","author":"Braaten","year":"2019","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2025090313382518000_8.1.e002195.36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5114\/ada.2019.83629","article-title":"Prevalence and severity of fatigue in psoriasis and psoriatic arthritis","volume":"37","author":"Krajewska-W\u0142odarczyk","year":"2020","journal-title":"Adv Dermatol Allergol"},{"key":"2025090313382518000_8.1.e002195.37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/bjd.15258","article-title":"Fatigue as a symptom in psoriasis and psoriatic arthritis: an observational study","volume":"176","author":"Tobin","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025090313382518000_8.1.e002195.38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13075-021-02680-y","article-title":"Sex-specific differences and how to handle them in early psoriatic arthritis","volume":"24","author":"Passia","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090313382518000_8.1.e002195.39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40744-020-00202-x","article-title":"The impact of comorbidity on patient-reported outcomes in psoriatic arthritis: a systematic literature review","volume":"7","author":"Ca\u00f1ete","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090313382518000_8.1.e002195.40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090313382518000_8.1.e002195.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2025090313382518000_8.1.e002195.42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.43","DOI":"10.1136\/annrheumdis-2020-217251"},{"key":"2025090313382518000_8.1.e002195.44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin Drug Investig"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.45","DOI":"10.1136\/rmdopen-2019-000990"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.46","DOI":"10.1002\/art.22443"},{"key":"2025090313382518000_8.1.e002195.47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40744-018-0120-8","article-title":"Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study","volume":"5","author":"de Vlam","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2025090313382518000_8.1.e002195.48","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.49","DOI":"10.1002\/art.30117"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.50","DOI":"10.3899\/jrheum.201532"},{"doi-asserted-by":"publisher","key":"2025090313382518000_8.1.e002195.51","DOI":"10.1136\/annrheumdis-2021-220991"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:38:38Z","timestamp":1756931918000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,16]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/rmdopen-2022-002195"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002195","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}